Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

Autor: Santos, J. R., Cozzi-Lepri, A., Phillips, A., De Wit, S., Pedersen, C., Reiss, P., Blaxhult, A., Lazzarin, A., Sluzhynska, M., Orkin, C., Duvivier, C., Bogner, J., Gargalianos-Kakolyris, P., Schmid, P., Hassoun, G., Khromova, I., Beniowski, M., Hadziosmanovic, V., Sedlacek, D., Paredes, R., Lundgren, J. D., Losso, M., Kundro, M., Schmied, B., Zangerle, R., Karpov, I., Vassilenko, A., Mitsura, V. M., Paduto, D., Clumeck, N., Delforge, M., Florence, E., Vandekerckhove, L., Begovac, J., Machala, L., Jilich, D., Kronborg, G., Benfield, T., Gerstoft, J., Katzenstein, T., Moller, N. F., Ostergaard, L., Wiese, L., Nielsen, L. N., Zilmer, K., Smidt, J., Ristola, M., Aho, I., Viard, J. -P., Girard, P. -M., Pradier, C., Fontas, E., Rockstroh, J., Schmidt, R., Degen, O., Stellbrink, H. J., Stefan, C., Fatkenheuer, G., Chkhartishvili, N., Gargalianos, P., Xylomenos, G., Lourida, P., Sambatakou, H., Szlavik, J., Gottfredsson, M., Mulcahy, F., Yust, I., Turner, D., Burke, M., Shahar, E., Elinav, H., Haouzi, M., Elbirt, D., Sthoeger, Z. M., D'Arminio Monforte, A., Esposito, R., Mazeu, I., Mussini, C., Mazzotta, F., Gabbuti, A., Vullo, V., Lichtner, M., Zaccarelli, M., Antinori, A., Acinapura, R., Plazzi, M., Castagna, A., Gianotti, N., Galli, M., Ridolfo, A., Rozentale, B., Uzdaviniene, V., Matulionyte, R., Staub, T., Hemmer, R., Ormaasen, V., Maeland, A., Bruun, J., Knysz, B., Gasiorowski, J., Inglot, M., Horban, A., Bakowska, E., Flisiak, R., Grzeszczuk, A., Parczewski, M., Pynka, M., Maciejewska, K., Mularska, E., Smiatacz, T., Gensing, M., Jablonowska, E., Malolepsza, E., Wojcik, K., Mozer-Lisewska, I., Caldeira, L., Mansinho, K., Maltez, F., Radoi, R., Panteleev, A., Panteleev, O., Yakovlev, A., Trofimora, T., Kuzovatova, E., Borodulina, E., Vdoushkina, E., Jevtovic, D., Tomazic, J., Gatell, J. M., Miro, J. M., Moreno, S., Rodriguez, J. M., Clotet, B., Jou, A., Tural, C., Puig, J., Bravo, I., Domingo, P., Gutierrez, M., Mateo, G., Sambeat, M. A., Laporte, J. M., Falconer, K., Thalme, A., Sonnerborg, A., Flamholc, L., Scherrer, A., Weber, R., Cavassini, M., Calmy, A., Furrer, H., Battegay, M., Kuznetsova, A., Kyselyova, G., Gazzard, B., Johnson, A. M., Simons, E., Edwards, S., Johnson, M. A., Mocroft, A., Weber, J., Scullard, G., Clarke, A., Leen, C., Gatell, J., Ledergerber, B., Kirk, O., Peters, L., Matthews, C., Fischer, A. H., Bojesen, A., Raben, D., Kristensen, D., Gronborg Laut, K., Larsen, J. F., Podlekareva, D., Shepherd, L., Schultze, A., Thiebaut, R., Burger, D.
Přispěvatelé: Santos, J. R., Cozzi-Lepri, A., Phillips, A., De Wit, S., Pedersen, C., Reiss, P., Blaxhult, A., Lazzarin, A., Sluzhynska, M., Orkin, C., Duvivier, C., Bogner, J., Gargalianos-Kakolyris, P., Schmid, P., Hassoun, G., Khromova, I., Beniowski, M., Hadziosmanovic, V., Sedlacek, D., Paredes, R., Lundgren, J. D., Castagna, A, on behalf of the EuroSIDA study, Group, AII - Infectious diseases, APH - Aging & Later Life, Infectious diseases, Global Health, Amsterdam institute for Infection and Immunity
Rok vydání: 2018
Předmět:
Male
0301 basic medicine
antiretroviral therapy-naïve patients
Lopinavir/ritonavir
darunavir
HIV Infections
Antiretroviral therapy-experienced patient
Gastroenterology
antiretroviral therapy-experienced patients
0302 clinical medicine
atazanavir/ritonavir
darunavir/ritonavir
lopinavir/ritonavir
Adult
Anti-HIV Agents
Antiretroviral Therapy
Highly Active
Europe
Female
Humans
Middle Aged
Prospective Studies
Treatment Outcome
Pharmacology (medical)
030212 general & internal medicine
atazanavir
Antiretroviral therapy-naïve patient
Health Policy
Lopinavir
Antiretroviral Therapy
Highly Active/methods
ritonavir
Infectious Diseases
Viral load
medicine.drug
medicine.medical_specialty
HIV Infections/drug therapy
Infectious Disease
antiretroviral therapy-naive patients
03 medical and health sciences
Internal medicine
medicine
Protease inhibitor (pharmacology)
Darunavir
business.industry
030112 virology
Atazanavir
lopinavir
Regimen
Anti-HIV Agents/therapeutic use
Ritonavir
business
Zdroj: Østergaard, L J & EuroSIDA Study Group 2018, ' Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe ', HIV Medicine, vol. 19, no. 5, pp. 324-338 . https://doi.org/10.1111/hiv.12581
Pedersen, C & on behalf of the EuroSIDA study group 2018, ' Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe ', HIV Medicine, vol. 19, no. 5, pp. 324-338 . https://doi.org/10.1111/hiv.12581
HIV medicine, 19(5), 324-338. Wiley-Blackwell
HIV Medicine
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
ISSN: 1468-1293
1464-2662
DOI: 10.1111/hiv.12581
Popis: OBJECTIVES: The aim of the study was to evaluate the long-term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)-, darunavir/ritonavir (DRV/r)-, and lopinavir/ritonavir (LPV/r)-containing regimens.METHODS: Data were analysed for 5678 EuroSIDA-enrolled patients starting a DRV/r-, ATZ/r- or LPV/r-containing regimen between 1 January 2000 and 30 June 2013. Separate analyses were performed for the following subgroups of patients: (1) ART-naïve subjects (8%) at ritonavir-boosted protease inhibitor (PI/r) initiation; (2) ART-experienced individuals (44%) initiating the new PI/r with a viral load (VL) ≤500 HIV-1 RNA copies/mL; and (3) ART-experienced patients (48%) initiating the new PI/r with a VL >500 copies/mL. Virological failure (VF) was defined as two consecutive VL measurements >200 copies/mL ≥24 weeks after PI/r initiation. Kaplan-Meier and multivariable Cox models were used to compare risks of failure by PI/r-based regimen. The main analysis was performed with intention-to-treat (ITT) ignoring treatment switches.RESULTS: The time to VF favoured DRV/r over ATZ/r, and both were superior to LPV/r (log-rank test; P < 0.02) in all analyses. Nevertheless, the risk of VF in ART-naïve patients was similar regardless of the PI/r initiated after controlling for potential confounders. The risk of VF in both treatment-experienced groups was lower for DRV/r than for ATZ/r, which, in turn, was lower than for LPV/r-based ART.CONCLUSIONS: Although confounding by indication and calendar year cannot be completely ruled out, in ART-experienced subjects the long-term effectiveness of DRV/r-containing regimens appears to be greater than that of ATZ/r and LPV/r.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje